Signum Biosciences, Inc. spins out Argyle Therapeutics, Inc. to develop Signum’s anti-inflammatory dermatology assets. Signum has assigned to Argyle all of the relevant intellectual property related to dermatological diseases. http://argyletherapeutics.com/about.html